Identification of cell-free microRNAs in the urine of patients with prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 1, 2015, Pages 16.e17-16.e22

  Korzeniewski, Nina ^a   Tosev, Georgi ^a   Pahernik, Sascha ^a   Hadaschik, Boris ^a   Hohenfellner, Markus ^a   Duensing, Stefan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

MiRNA; Prostate cancer; Urine

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 125B; MICRORNA 141; MICRORNA 16; MICRORNA 200B; MICRORNA 200C; MICRORNA 205; MICRORNA 22; MICRORNA 24; MICRORNA 29A; MICRORNA 29B; MIRNA 1275; MIRNA 1290; MIRNA 483 5P; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CARCINOGENESIS; CELL FREE SYSTEM; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EXOSOME; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LNCAP CELL LINE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE EPITHELIUM CELL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA ISOLATION; RNA PROCESSING; RNA TRANSLATION; SENSITIVITY AND SPECIFICITY; STUDY; TRANSCRIPTION INITIATION; URINALYSIS; URINE LEVEL; AGED; GENETICS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; URINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 84922654822     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.09.015     Document Type: Article

References (31)

1. Schroder F.H. Review of diagnostic markers for prostate cancer. Recent Results Cancer Res 2009, 181:173-182.
2. Nadler R.B., Humphrey P.A., Smith D.S., Catalona W.J., Ratliff T.L. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995, 154:407-413.
3. Tchetgen M.B., Oesterling J.E. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am 1997, 24:283-291.
4. Klotz L. Prostate cancer overdiagnosis and overtreatment. Curr Opin Endocrinol Diabetes Obes 2013, 20:204-209.
5. Loeb S., Bjurlin M.A., Nicholson J., Tammela T.L., Penson D.F., Carter HB. Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014, 65:1046-1055.
6. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
7. Hart M., Nolte E., Wach S., Szczyrba J., Taubert H., Rau T.T. Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing. Mol Cancer Res 2014, 12:250-263.
8. Garzon R., Calin G.A., Croce C.M. MicroRNAs in cancer. Annu Rev Med 2009, 60:167-179.
9. Cortez M.A., Bueso-Ramos C., Ferdin J., Lopez-Berestein G., Sood A.K., Calin G.A. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011, 8:467-477.
10. Schwarzenbach H., Nishida N., Calin G.A., Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 2014, 11:145-156.
11. Kuner R., Brase J.C., Sultmann H., Wuttig D. microRNA biomarkers in body fluids of prostate cancer patients. Methods 2013, 59:132-137.
12. Kelly B.D., Miller N., Healy N.A., Walsh K., Kerin M.J. A review of expression profiling of circulating microRNAs in men with prostate cancer. BJU Int 2013, 111:17-21.
13. Bryant R.J., Pawlowski T., Catto J.W., Marsden G., Vessella R.L., Rhees B. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012, 106:768-774.
14. Haj-Ahmad T.A., Abdalla M.A., Haj-Ahmad Y. Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer 2014, 5:182-191.
15. Srivastava A., Goldberger H., Dimtchev A., Ramalinga M., Chijioke J., Marian C. MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214. PLoS One 2013, 8:e76994.
16. Mlcochova H., Hezova R., Stanik M., Slaby O. Urine microRNAs as potential noninvasive biomarkers in urologic cancers. Urol Oncol 2014, 32:41. [e41-49].
17. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001, 98:5116-5121.
18. Kuru T.H., Roethke M.C., Seidenader J., Simpfendörfer T., Boxler S., Alammar K. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J Urol 2013, 190:1380-1386.
19. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
20. Kroh E.M., Parkin R.K., Mitchell P.S., Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010, 50:298-301.
21. Soon P.S., Tacon L.J., Gill A.J., Bambach C.P., Sywak M.S., Campbell P.R. miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res 2009, 15:7684-7692.
22. Patterson E.E., Holloway A.K., Weng J., Fojo T., Kebebew E. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011, 117:1630-1639.
23. Shen J., Wang A., Wang Q., Gurvich I., Siegel A.B., Remotti H. Exploration of genome-wide circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a potential biomarker. Cancer Epidemiol Biomarkers Prev 2013, 22:2364-2373.
24. Song Q., Xu Y., Yang C., Chen Z., Jia C., Chen J. miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. Cancer Res 2014, 74:3031-3042.
25. Wang L., Shi M., Hou S., Ding B., Liu L., Ji X. MiR-483-5p suppresses the proliferation of glioma cells via directly targeting ERK1. FEBS Lett 2012, 586:1312-1317.
26. Qiao Y., Ma N., Wang X., Hui Y., Li F., Xiang Y. MiR-483-5p controls angiogenesis in vitro and targets serum response factor. FEBS Lett 2011, 585:3095-3100.
27. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011, 108:5003-5008.
28. Turchinovich A., Weiz L., Langheinz A., Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011, 39:7223-7233.
29. Rivas F.V., Tolia N.H., Song J.J., Aragon J.P., Liu J., Hannon G.J. Purified Argonaute2 and an siRNA form recombinant human RISC. Nat Struct Mol Biol 2005, 12:340-349.
30. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9:654-659.
31. Turchinovich A., Samatov T.R., Tonevitsky A.G., Burwinkel B. Circulating miRNAs: cell-cell communication function?. Front Genet 2013, 4:119.